Document Detail

Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
MedLine Citation:
PMID:  16275091     Owner:  NLM     Status:  MEDLINE    
Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy.
Marcella Caggiula; Anna Paola Batocchi; Giovanni Frisullo; Francesco Angelucci; Agata Katia Patanella; Cristina Sancricca; Viviana Nociti; Pietro Attilio Tonali; Massimiliano Mirabella
Publication Detail:
Type:  Journal Article     Date:  2005-11-07
Journal Detail:
Title:  Clinical immunology (Orlando, Fla.)     Volume:  118     ISSN:  1521-6616     ISO Abbreviation:  Clin. Immunol.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-02     Completed Date:  2006-03-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883537     Medline TA:  Clin Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  77-82     Citation Subset:  IM    
Institute of Neurology, Catholic University, Largo Gemelli 8, 00168 Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cells, Cultured
Interferon-beta / therapeutic use*
Leukocytes, Mononuclear / immunology,  metabolism*
Middle Aged
Multiple Sclerosis, Chronic Progressive / blood*,  drug therapy
Multiple Sclerosis, Relapsing-Remitting / blood*,  drug therapy
Nerve Growth Factors / biosynthesis*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Nerve Growth Factors; 145155-23-3/interferon beta-1b; 145258-61-3/interferon beta 1a; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and ...
Next Document:  Minimally invasive surgical techniques for stress incontinence surgery.